HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma

2020

HemaSphere , Volume 4 - Issue 1

Additional Metadata
Persistent URL	doi.org/10.1097/hs9.0000000000000325, hdl.handle.net/1765/128616
Journal	HemaSphere
Organisation	Department of Hematology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Stevens, WBC, Bakunina, K., Cuijpers, M., Chamuleau, M., Beeker, A., Fijnheer, R., … Kersten, M. J. (2020). HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma. HemaSphere, 4(1). doi:10.1097/hs9.0000000000000325

Publication